Results 191 to 200 of about 118,027 (327)

Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Many patients with inflammatory bowel disease (IBD) do not adequately respond to infliximab, potentially due to individual differences in pharmacokinetics (PK). This study aimed to identify clinical and biochemical variables associated with infliximab PK.
Ilse A. Pool   +6 more
wiley   +1 more source

Familial Spondylitis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1971
R, Bennett, E G, Bywaters, P J, Holt
openaire   +2 more sources

Epiglottic Ulceration as an Initial Manifestation of Crohn's Disease

open access: yesJournal of General and Family Medicine, Volume 27, Issue 1, January 2026.
ABSTRACT Crohn's disease can present with various extraintestinal symptoms; however, laryngeal involvement, particularly epiglottic ulcers, is rare. A 52‐year‐old man presented with a sore throat. Laryngeal endoscopy revealed an epiglottic ulcer. He had no gastrointestinal symptoms.
Niina Yamashita   +2 more
wiley   +1 more source

Patterns of complementary and alternative medicine use in pediatric patients with inflammatory bowel disease

open access: yesJournal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 1, Page 84-92, January 2026.
Abstract Objectives Inflammatory bowel disease (IBD) constitutes a challenging and long‐lasting burden for pediatric patients. The management of IBD is multifaceted involving conventional medication but also dietary measures. An increasing number of patients are turning to complementary and alternative medicine (CAM) in their quest to alleviate IBD ...
Katharina Guilcher   +12 more
wiley   +1 more source

Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Infliximab, a monoclonal antibody used for immune‐mediated diseases, shows high interpatient pharmacokinetic variability. Prolonged exposure increases the risk of adverse effects and costs, making dose personalization essential to balance safety, efficacy, and cost‐effectiveness. Population pharmacokinetic models support individualized dosing,
Sahira Chaiben   +4 more
wiley   +1 more source

Alterations in the Gut Microbiome in Ankylosing Spondylitis and Their Correlation with Disease Activity. [PDF]

open access: yesJ Microbiol Biotechnol
Jeong H   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy